Samrotamab  (Synonyms: PR-1498487)

Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

LRRC15

131578  [NCBI]

Q8TF66

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.92 kDa

2052591-32-7

Liquid

Colorless to light yellow

[Samrotamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Samrotamab on AHC2 biosensor, can bind LRRC15 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78172) with an affinity constant of 5.759E-10 M as determined in BLI assay.

• [1]. Dong SW, et al. The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. Am J Cancer Res. 2025 May 25;15(5):2301-2318.

  [2]. Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 1;27(13):3556-3566.  [Content Brief]

  [3]. Jonathan Gill and Richard Gorlick, dvancing therapy for osteosarcoma. Nat Rev Clin Oncol. 609–624 (2021).